(1S 4S)-(-)-2-(4-CHLOROPHENYL)-2 5-DIAZ&
- $215.49 - $771.31
- Product name: (1S 4S)-(-)-2-(4-CHLOROPHENYL)-2 5-DIAZ&
- CAS: 308103-51-7
- MF: C11H15Br2ClN2
- MW: 370.5112
- EINECS:
- MDL Number:MFCD01321296
- Synonyms:(1S,4S)-2-(4-CHLOROPHENYL)-2,5-DIAZABI-C YCLO(2.2.1)HEPTANE DIHYDROBROMIDE;(1S 4S)-(-)-2-(4-CHLOROPHENYL)-2 5-DIAZ&
3 prices
Selected condition:
Brand
- American Custom Chemicals Corporation
- Chem-Impex
- Sigma-Aldrich
Package
- 500MG
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberCHM0032764
- Product description(1S,4S)-(-)-2-(4-CHLOROPHENYL)-2,5-DIAZABICYCLO[2.2.1]HEPTANE HYDROBROMIDE 95.00%
- Packaging500MG
- Price$771.31
- Updated2021-12-16
- Buy
- ManufacturerChem-Impex
- Product number41603
- Product description(1S,4S)-(−)-2-(4-Chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane hydrobromide
- Packaging500MG
- Price$215.49
- Updated2021-12-16
- Buy
- ManufacturerSigma-Aldrich
- Product number473391
- Product description(1S,4S)-(?)-2-(4-Chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane hydrobromide
- Packaging500mg
- Price$406
- Updated2023-06-20
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
American Custom Chemicals Corporation | CHM0032764 | (1S,4S)-(-)-2-(4-CHLOROPHENYL)-2,5-DIAZABICYCLO[2.2.1]HEPTANE HYDROBROMIDE 95.00% | 500MG | $771.31 | 2021-12-16 | Buy |
Chem-Impex | 41603 | (1S,4S)-(−)-2-(4-Chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane hydrobromide | 500MG | $215.49 | 2021-12-16 | Buy |
Sigma-Aldrich | 473391 | (1S,4S)-(?)-2-(4-Chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane hydrobromide | 500mg | $406 | 2023-06-20 | Buy |
Properties
Melting point :229 °C (dec.)(lit.)
optical activity :[α]23/D 94°, c = 1 in H2O
optical activity :[α]23/D 94°, c = 1 in H2O
Safety Information
Symbol(GHS): | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|